SWShubin Wang

Shubin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shubin Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Boran Cheng

    Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Gangling Tong

    Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Jingzhang Li

    Department of Oncology, Liuzhou People's Hospital, Liuzhou, China

    1 shared publication
  • Laiqing Li

    Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, China

    1 shared publication
  • Lirui He

    Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Qiaohong Nong

    Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication

Latest Publications

  • Open Access

    MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells

    by Gangling Tong, Boran Cheng, Jingzhang Li, Xuan Wu, Qiaohong Nong, Lirui He, Xi Li, Laiqing Li, Shubin Wang

    Background: Immunotherapy and its mechanisms are being studied in a wide variety of cancers. Programmed cell death ligand 1 (PDL1) is associated with immune evasion in numerous tumor types. Here, we aimed to assess the relationship between metastasis associated in colon cancer‐1 (MACC1) and PDL1 and examine their effects on gastric cancer (GC) tumor immunity.Methods: The expression of MACC1, c‐Met, and PDL1 in human GC tissues was first assessed using quantitative RT‐PCR (qRT‐PCR) and immunohistochemistry. We then focused on the relationships among MACC1, c‐Met, and PDL1 using RT‐PCR and western blotting after cell transfection and inhibitor treatment in vitro and on the identification of their roles in immune killing in vitro and in vivo.Results: We found that expression of MACC1, c‐Met, and PDL1 was upregulated in human GC tissues, and there was a positive correlation between the expression levels. In addition, we found that ectopic expression of MACC1 (silencing and overexpression by transfection) resulted in corresponding changes in c‐Met and PDL1 expression levels, and c‐Met/AKT/mTOR pathway inhibitors (SU11274, MK2206, and rapamycin) blocked the regulation of PDL1 expression by MACC1. Furthermore, silencing of MACC1 led to an increase in antitumor and immune killing in vitro and in vivo, and overexpression of MACC1 resulted in a decrease in tumor immunity in vitro and in vivo.Conclusions: From these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy.